SCHEDULE 13G - IRONWOOD PHARMACEUTICALS INC (0001446847) (Subject)

8-K - IRONWOOD PHARMACEUTICALS INC (0001446847) (Filer)

10-Q - IRONWOOD PHARMACEUTICALS INC (0001446847) (Filer)

8-K - IRONWOOD PHARMACEUTICALS INC (0001446847) (Filer)

8-K - IRONWOOD PHARMACEUTICALS INC (0001446847) (Filer)

10-Q - IRONWOOD PHARMACEUTICALS INC (0001446847) (Filer)

8-K - IRONWOOD PHARMACEUTICALS INC (0001446847) (Filer)

8-K - IRONWOOD PHARMACEUTICALS INC (0001446847) (Filer)

8-K - IRONWOOD PHARMACEUTICALS INC (0001446847) (Filer)

10-Q - IRONWOOD PHARMACEUTICALS INC (0001446847) (Filer)

4 - IRONWOOD PHARMACEUTICALS INC (0001446847) (Issuer)

4 - IRONWOOD PHARMACEUTICALS INC (0001446847) (Issuer)

4 - IRONWOOD PHARMACEUTICALS INC (0001446847) (Issuer)

4 - IRONWOOD PHARMACEUTICALS INC (0001446847) (Issuer)

4 - IRONWOOD PHARMACEUTICALS INC (0001446847) (Issuer)

4 - IRONWOOD PHARMACEUTICALS INC (0001446847) (Issuer)

4 - IRONWOOD PHARMACEUTICALS INC (0001446847) (Issuer)

4 - IRONWOOD PHARMACEUTICALS INC (0001446847) (Issuer)

4 - IRONWOOD PHARMACEUTICALS INC (0001446847) (Issuer)

4 - IRONWOOD PHARMACEUTICALS INC (0001446847) (Issuer)

4 - IRONWOOD PHARMACEUTICALS INC (0001446847) (Issuer)

4 - IRONWOOD PHARMACEUTICALS INC (0001446847) (Issuer)

4 - IRONWOOD PHARMACEUTICALS INC (0001446847) (Issuer)

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) today announced that Sravan Emany, Chief Operating Officer and Chief Financial Officer, will participate in a fireside chat at the Jefferies London Healthcare Conference on Wednesday, November 20, 2024 at 7:30 a.m. GT at the Waldorf Hilton in London. A live webcast of Ironwood's fireside chat will be accessible through the Investors section of the company's website at www.ironwoodpharma.com. A replay of the webcast will be available on Ironwood's website for 1 year following the conference. About Ironwood Pharmaceuticals Ironwood Pharmaceuticals (NASDAQ:IRWD), an S&P SmallCap 600® company, is a leading gastrointestinal (GI) healthcare company

– LINZESS® (Iinaclotide) EUTRx prescription demand growth of 13% year-over-year – – Remains on track to complete apraglutide NDA submission in Q1 2025 – – Maintains Full Year 2024 Financial Guidance – Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD), a GI-focused healthcare company, today reported its third quarter 2024 results and recent business performance. "LINZESS continued to deliver robust prescription demand growth in the third quarter," said Tom McCourt, chief executive officer of Ironwood Pharmaceuticals. "LINZESS extended units and new-to-brand prescriptions each increased 13% year-over-year, respectively, reinforcing that patients and health care professionals continue to choose

– New safety and tolerability data show high treatment compliance with apraglutide, low incidence of injection site reactions and adverse events associated with GI tolerability – – Findings reinforce the clinical profile of once-weekly apraglutide; Ironwood expects to complete U.S. regulatory submission in Q1 2025 – – One apraglutide poster recognized as presidential poster recipient – – New linaclotide data shed light on treatment outcomes across patient demographics – Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD), a GI-focused healthcare company, will present new findings at the American College of Gastroenterology (ACG) 2024 Annual Scientific Meeting and Postgraduate Course from subgr

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) today announced it will host its third quarter 2024 investor update conference call and webcast at 8:30 a.m. Eastern Time on Thursday, November 7, 2024. Individuals interested in participating in the call should dial (888) 596-4144 (U.S. and Canada) or (646) 968-2525 (international) using conference ID number and event passcode 2530602. To access the webcast, please visit the Investors section of Ironwood's website at www.ironwoodpharma.com. The call will be available for replay via telephone starting Thursday, November 7, 2024 at approximately 11:30 a.m. Eastern Time, running through 11:59 p.m. Eastern Time on Thursday, November 21, 2024. To li

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) will participate in a fireside chat at the 2024 Wells Fargo Healthcare Conference on Thursday, September 5, 2024 at 2:15 p.m. ET at the Encore Boston Harbor. A live webcast of Ironwood's fireside chat will be accessible through the Investors section of the company's website at www.ironwoodpharma.com. A replay of the webcast will be available on Ironwood's website for 1 year following the conference. About Ironwood Pharmaceuticals Ironwood Pharmaceuticals (NASDAQ:IRWD), an S&P SmallCap 600® company, is a leading gastrointestinal (GI) healthcare company on a mission to advance the treatment of GI diseases and redefine the standard of care for

– LINZESS® (linaclotide) EUTRx prescription demand growth of 11% year-over-year – – Plans to pursue apraglutide rolling NDA review; expects to complete submission in the first quarter of 2025 – – On track to deliver CNP-104 topline results in the third quarter of 2024 – – Revises FY 2024 financial guidance due to continued LINZESS pricing pressure associated with higher-than-expected Medicaid utilization trends – Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD), a GI-focused healthcare company, today reported its second quarter 2024 results and recent business performance. "We continued to make progress across our portfolio in the second quarter," said Tom McCourt, chief executive off

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) today announced it will host its second quarter 2024 investor update conference call and webcast at 8:30 a.m. Eastern Time on Thursday, August 8, 2024. Individuals interested in participating in the call should dial (888) 596-4144 (U.S. and Canada) or (646) 968-2525 (international) using conference ID number and event passcode 2530602. To access the webcast, please visit the Investors section of Ironwood's website at www.ironwoodpharma.com. The call will be available for replay via telephone starting Thursday, August 8, 2024 at approximately 11:30 a.m. Eastern Time, running through 11:59 p.m. Eastern Time on Thursday, August 22, 2024. To listen

PRESS RELEASE Memo Therapeutics AG appoints Paul Carter as Chairperson Virology and commercial expertise will support Phase III readiness and commercial preparations of AntiBKV Extensive public and private market experience following executive positions in numerous biopharma companies                  Schlieren / Zurich, Switzerland, 8 July, 2024 – Memo Therapeutics AG (or "MTx"), a late-stage biotech company translating unique immune responses into superior medicines to treat viral infections and cancer, today announces the appointment of Paul Carter as Chairperson of the Board of Directors. Paul has had an extensive executive career in the biopharma space, with commercial a

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) today announced that Sravan Emany, Chief Financial Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Thursday, June 6, 2024 at 9:00 a.m. ET at the Marriott Marquis in New York City. A live webcast of Ironwood's fireside chat will be accessible through the Investors section of the company's website at www.ironwoodpharma.com. To access the webcast, please log on to the Ironwood website approximately 15 minutes prior to the start time to ensure adequate time for any software downloads that may be required. A replay of the webcast will be available on Ironwood's website for 1 year following the conference

– New data highlight both stoma and colon-in-continuity (CIC) patients drove the positive primary endpoint with significant relative change from baseline in weekly parenteral support (PS) volume reduction at week 24 – – Additional secondary endpoints show significant increases in days off PS and clinical responder rates with apraglutide, including achieving enteral autonomy in both stoma and CIC patients – – Data from largest GLP-2 Phase III study to date adds to body of evidence on safety and efficacy of once-weekly apraglutide in adults with SBS-IF – – New details on safety and tolerability to be presented; showing apraglutide to be well tolerated with a safety profile consistent wi

Leerink Partners initiated coverage of Ironwood Pharma with a rating of Market Perform and set a new price target of $5.00

CapitalOne downgraded Ironwood Pharma from Overweight to Equal Weight and set a new price target of $4.00 from $12.00 previously

Craig Hallum initiated coverage of Ironwood Pharma with a rating of Buy and set a new price target of $21.00

Wells Fargo initiated coverage of Ironwood Pharma with a rating of Overweight and set a new price target of $20.00

Jefferies initiated coverage of Ironwood Pharma with a rating of Buy and set a new price target of $21.00

JMP Securities initiated coverage of Ironwood Pharma with a rating of Mkt Outperform and set a new price target of $22.00

CapitalOne initiated coverage of Ironwood Pharma with a rating of Overweight and set a new price target of $15.00

Piper Sandler initiated coverage of Ironwood Pharma with a rating of Overweight and set a new price target of $16.00

Morgan Stanley reiterated coverage of Ironwood Pharmaceuticals with a rating of Equal-Weight and set a new price target of $14.00 from $13.00 previously

Morgan Stanley reiterated coverage of Ironwood Pharmaceuticals with a rating of Equal-Weight and set a new price target of $12.00 from $11.00 previously

PRESS RELEASE Memo Therapeutics AG appoints Paul Carter as Chairperson Virology and commercial expertise will support Phase III readiness and commercial preparations of AntiBKV Extensive public and private market experience following executive positions in numerous biopharma companies                  Schlieren / Zurich, Switzerland, 8 July, 2024 – Memo Therapeutics AG (or "MTx"), a late-stage biotech company translating unique immune responses into superior medicines to treat viral infections and cancer, today announces the appointment of Paul Carter as Chairperson of the Board of Directors. Paul has had an extensive executive career in the biopharma space, with commercial a

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD), a GI-focused healthcare company, today announced the appointment of Sravan K. Emany as senior vice president, chief financial officer. Mr. Emany will become a member of Ironwood's Leadership Team and be responsible for all financial operations of the company, including financial planning and reporting, tax, accounting, and investor relations effective December 6, 2021. He will report to Thomas McCourt, chief executive officer of Ironwood. Mr. McCourt commented, "We always look to our mission to guide our efforts to deliver the highest value to our stakeholders. We believe Sravan's deep financial and corporate strategy capabilities within the he

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD), a GI-focused healthcare company, today announced the appointment of John Minardo as senior vice president, chief legal officer. Mr. Minardo will become a member of Ironwood's Leadership Team and oversee the company's Corporate Legal, Compliance and IP teams. He will report to Thomas McCourt, chief executive officer of Ironwood. Mr. McCourt commented, "John's deep legal experience and proven track record, in particular his experience at highly focused healthcare companies, arm him with invaluable expertise that will strongly benefit Ironwood by helping accelerate our business priorities and reinforce our efforts to make a difference for people l

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), a GI-focused healthcare company, today announced that the Board of Directors named Thomas McCourt, who has served as president and interim chief executive officer since March 12, 2021, as permanent chief executive officer. Mr. McCourt has also been appointed to serve on Ironwood’s Board. With the appointment of Mr. McCourt, the Board is now comprised of 11 directors. Ironwood also announced that Gina Consylman plans to step down as senior vice president and chief financial officer, effective July 2, 2021, in order to pursue another leadership opportunity at a rare disease biotechnology company. Ms. Consylman’

Patrik De Haes M.D. becomes Non-executive Chairman Leuven, BE and Boston, MA, US – May 17, 2021 – 7:30 AM CET – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with a clinical stage portfolio in retinal vascular disorders, announces in a planned succession, the promotion of Tom Graney, CFA from Chief Financial Officer (CFO) to Chief Executive Officer (CEO) of the company. He takes over from Dr. Patrik De Haes, who after 14 years as CEO, has decided to move away from day-to-day management of the company to become the Non-executive Chairman of Oxurion. Thomas Clay, the outgoing Chairman of Oxurion, will remain

– LINZESS® (Iinaclotide) U.S. net sales of $215 million, an increase of 12% year-over-year – –Total revenue of $89 million, an increase of 11% year-over-year, driven primarily by U.S. LINZESS collaboration revenue of $86 million – – GAAP net income of $40 million and adjusted EBITDA of $46 million; ended Q1 2021 with $438 million in cash and cash equivalents – – Maintaining full year 2021 financial guidance – Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD), a GI-focused healthcare company, today provided an update on its first quarter 2021 results and recent business performance. "We are off to a solid start to the year, as LINZESS continued the strong momentum we saw in 2020," said Tom M

BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) today announced the appointment of Jay P. Shepard to its Board of Directors, effective immediately. Mr. Shepard will also serve as a member of the Audit Committee. Following the appointment of Mr. Shepard, the Board is now composed of 11 directors, nine of whom are independent. “We are excited to welcome Jay to Ironwood’s Board. Jay is a recognized leader within our industry with nearly three decades of expertise as an accomplished public company CEO and senior executive,” said Julie McHugh, chair of Ironwood’s Board. “We look forward to leveraging Jay’s deep expertise as we seek to further our mission to adva

U.S. stocks were mixed, with the Dow Jones index gaining around 50 points on Friday. Shares of Asana, Inc. (NYSE:ASAN) rose sharply during Friday's session after the company announced a $150 million share repurchase program and reaffirmed its forward guidance. Asana said its board of directors approved a stock repurchase program authorizing the company to repurchase up to $150 million of its Class A common stock through June 30, 2025. Asana shares jumped 13.4% to $12.90 on Friday. Here are some other big stocks recording gains in today’s session. Sarepta Therapeutics, Inc. (NASDAQ:SRPT) shares jumped 39.2% to $171.89 after the company announced FDA approval of an expansion to

- Form8

New data highlight both stoma and colon-in-continuity (CIC) patients drove the positive primary endpoint with significant relative change from baseline in weekly parenteral support (PS) volume reduction at week 24 Additional secondary endpoints show significant increases in days off PS and clinical responder rates with apraglutide, including achieving enteral autonomy in both stoma and CIC patients – Data from largest GLP-2 Phase III study to date adds to body of evidence on safety and efficacy of once-weekly apraglutide in adults with SBS-IF – New details on safety and tolerability to be presented; showing apraglutide to be well tolerated with a safety profile consistent with previousl

Craig-Hallum analyst Chase Knickerbocker maintains Ironwood Pharmaceuticals (NASDAQ:IRWD) with a Buy and lowers the price target from $18 to $14.

Shares of Duolingo, Inc. (NASDAQ:DUOL) fell sharply during Thursday's session after the company reported first quarter financial results. Duolingo reported quarterly earnings of 57 cents per share which beat the analyst consensus estimate of 27 cents by 111.11%. Quarterly sales came in at $167.6 million which beat the analyst consensus estimate of $165.677 million and is a 44.91% increase from the same period last year, according to data from Benzinga Pro. Duolingo sees second-quarter revenues of between $175 million and $177.5 million, versus the $176.9 million estimate and full-year 2024 revenues of between $726.5 million and $735.5 million, versus the $728.23 million estimate. Du

Gainers Zai Lab (NASDAQ:ZLAB) stock increased by 21.5% to $20.14 during Thursday's pre-market session. The market value of their outstanding shares is at $1.9 billion. As per the news, the Q1 earnings report came out yesterday. ZimVie (NASDAQ:ZIMV) shares moved upwards by 20.28% to $18.5. The market value of their outstanding shares is at $503.5 million. The company's, Q1 earnings came out yesterday. Aadi Bioscience (NASDAQ:AADI) shares moved upwards by 16.84% to $2.15. The company's market cap stands at $52.7 million. As per the press release, Q1 earnings came out yesterday. CEL-SCI (AMEX:CVM) shares moved upwards by 14.38% to $1.59. The company's market cap stands at $85.8 million. Ta

Ironwood 2024 Financial Guidance. Ironwood has revised its FY 2024 financial guidance due to a LINZESS gross-to-net change in estimate related to the year ended December 31, 2023. Ironwood now expects:   Prior 2024 Guidance (February 15, 2024) Revised 2024 Guidance2 (May 9, 2024) U.S. LINZESS Net Sales3 Low-single digits % growth Mid-single digits % decline Total Revenue $435 to $455 million $405 to $425 million Adjusted EBITDA1 >$150 million Excludes potential CNP-104 option exercise >$120 million Excludes potential CNP-1

Ironwood Pharmaceuticals (NASDAQ:IRWD) reported quarterly losses of $(0.02) per share which missed the analyst consensus estimate of $0.19 by 110.53 percent. This is a 108 percent decrease over earnings of $0.25 per share from the same period last year. The company reported quarterly sales of $74.877 million which missed the analyst consensus estimate of $105.804 million by 29.23 percent. This is a 28.05 percent decrease over sales of $104.061 million the same period last year.

First prospective trial of a glucagon-like peptide (GLP-2) analog in SR GI aGVHD. Results up to Day 91 show that apraglutide in SR GI aGVHD was well-tolerated with an acceptable safety profile, the study's primary objective. Exploratory secondary efficacy data showed lower GI tract responses maintained through Day 91 in SR GI aGVHD patients treated with apraglutide and standard of care.

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength on days when prices go down. When compared to a stock's price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered oversold when the RSI is below 30, according to Benzinga Pro. Here’s the latest list of major oversold players in this sector, having an RSI near or below 30. Pacific Biosciences of California, Inc. (NASDAQ:PACB) On Feb. 15, Pacific Biosciences posted a narrower-than-expected quarterly l